info@biomedres.us   +1 (720) 414-3554
  One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA

Biomedical Journal of Scientific & Technical Research

June, 2021, Volume 36, 3, pp 28539-28542

Research Article

Research Article

Proof of Concept Study to Investigate the Association Between Autovaccines and COVID-19 Incidence in Patients with Recurrent Respiratory Diseases

Jaime Leache Pueyo1, Laura Pérez Delgado1, José Victor Tisner Nieto2, Mª Carmen Orte Aldea3, Raquel Artal Sánchez2, María Matas Ros4 and Inmaculada Buendía Jiménez4*

Author Affiliations

1Hospital Universitario Miguel Servet, ENT Service, Zaragoza, Spain

2ENT Clinic, Zaragoza, Spain

3ENT Service, Huesca, Spain

4Probelte Pharma S.L.U, Murcia, Spain

Received: June 01, 2021 | Published: June 11, 2021

Corresponding author: Inmaculada Buendía Jiménez, Probelte Pharma S.L.U, Murcia, Spain

DOI: 10.26717/BJSTR.2021.36.005853

Abstract

Introduction: Exposure to bacterial components can activate innate immunity and “train” it.

This phenomenon is crucial in the fight against infectious diseases, including COVID-19. The objective of this study is to assess whether a bacterial autovaccine could protect against SARS-CoV-2 thanks to trained innate immunity.

Methods: A retrospective controlled study that was carried out in four ENT services in Spain. Patients aged between 18 and 80 years of age with recurrent upper respiratory tract infections who received the bacterial autovaccine during a period between January 2019 and April 2020 were selected. The control group was made up of a selection of patients who presented a pathology in the ENT area and who did not receive the bacterial autovaccine during the same period. The study was approved by the regional Ethics Committee of Aragon. The main parameter was cumulative incidence, i.e., the proportion of people who contracted COVID-19 and had been diagnosed by PCR or serology in the period between March and August 2020 in each group.

Results: 129 patients were included in the autovaccine group and 149 patients in the control group. Both groups had a similar demographic and clinical distribution. The group treated with the autovaccine had a significantly lower incidence of COVID-19 than the control group (2.3% vs 8.7%, p <0.05).

Conclusion: These results suggest that the bacterial autovaccine could protect against COVID-19 as the cumulative incidence in the autovaccine group is almost four times lower than in the control group. Controlled clinical trials are necessary to confirm these data.

Keywords: Autovaccine; Bacterial Lysate; COVID-19; Trained Innate Immunity

Introduction

Bacterial lysate vaccines are indicated for the prevention of recurrent respiratory infections in adults and children [1-3]. This treatment enhances the adaptative response against the specific pathogens contained in the vaccine. Additionally, it also boosts the baseline tone of innate immunity by developing immunological long-term memory and improving the cross protection from other pathogens [4, 5]. This process is known as trained immunity and may have an important role in the fight against infectious diseases, including COVID-19 [6-8]. On the basis of this data, we hypothesized that the bacterial autovaccines may be a preventive measure against SARS-CoV-2.

Materials and Methods

We did a multicenter retrospective case-control study of data from the ENT department at 3 hospitals and one clinic in the region of Aragon (Spain) to estimate the autovaccine effectiveness against the COVID-19. Our study population included people aged between 18 and 80 years of age who were diagnosed with recurrent upper respiratory tract infections at the participating medical sites, and who had received the autovaccine (Probelte Pharma, Murcia, Spain) during a period between January 2019 and April 2020. The control group consisted of a random selection of patients diagnosed with a chronic ENT pathology during the same period at the investigator sites. Data sources were the medical history, which included COVID-19 diagnoses. This has been routinely recorded in the patient medical history at regular medical consultations since the beginning of the pandemic in March 2020. The data about the COVID-19 infection was provided for the period between March and August 2020. We obtained ethical approval from the regional Ethics Committee in Aragon (CEICA). The autovaccine is a bacterial lysate from bacterial germens isolated from the respiratory mucosa of each patient. The vaccine was sublingually administered daily for at least 3 months before the COVID-19 diagnostic test. The primary outcome of the study was the cumulative incidence, i.e., the proportion of people who contracted the COVID-19 disease and had been diagnosed by a PCR or serology test, in the period between March and August 2020 in each study group. The secondary outcomes were the proportion of patients hospitalized and in intensive care units because of the infection. Data were reported as means and standard deviations after checking for normality of distribution. Paired t-tests for independent groups and Chi-square tests were used to compare values between the groups. The study was not statistically powered given the exploratory design and the absence of previous literature on the topic.

Results

A total of 140 patients received the autovaccine at the participant investigator sites during the study period. Finally, 129 patients met the inclusion criteria in the autovaccine group and 149 patients in the control group (Figure 1). Overall, baseline demographic and clinical parameters were similar in treated and control patients Table 1. The mean (SD) age of all patients was 52 (17) years, and the mean body mass index (SD) was 26 [6]. The majority of patients received a mixture of two bacteria and 80% of them contained Streptococcus species, including pneumoniae, viridans and pyogenes (Figure 2). The autovaccine group had a significant lower cumulative incidence of COVID-19 compared with the control group. The proportion of patients who contracted COVID-19 in the treated group was 2.3% and, in the control, group was 8.7%, meaning a difference between groups of 74% (p<0.05). The proportion of patients hospitalized and in ICUs was also higher in the control group but did not reach a statistical difference.

Figure 1: Autovaccine bacterial composition.

Figure 2: Study flow chart.

Table 1: Baseline characteristics of the population.

Discussion

This data suggests that the autovaccine may protect against COVID-19 since the cumulative incidence in the treated group in almost four times lower than in the control group. As with any observational study, this analysis has some limitations. The results may be influenced by a limited sample size and slight differences between the groups at baseline. The control group had a lower proportion of males and a slightly higher prevalence of cancer and chronic kidney disease compared to the autovaccine group. However, previous studies have reported that this may not impact the incidence of COVID-19 [9,10]. Conversely, the study has several strengths. The study population is representative of the general population, the COVID-19 diagnosis was confirmed by a physician and a rigorous procedure was followed to obtain a random selection of control patients from the appointment list at each site. At present, it is crucial to explore new options to control the worldwide COVID-19 pandemic. A number of conventional anti infection vaccines with heterologous protection are under investigation. About 200 hundred studies have been published to assess the effectiveness of the anti-tuberculosis (BCG) vaccine against COVID-19. The results remain controversial and several clinical trials are under way. The bacterial lysates vaccines from respiratory pathogens can also train immunity to more efficiently fight heterogeneous pathogens. Additionally, some pathogens such as Streptococcus pneumoniae, included in the autovaccines administered in the study, may have a potential cross reactivity immunity to SARS-COV-2, as described by Roche et al. [11]. However, apparently no study has yet assessed the protective role of the autovaccine or bacterial lysate to fight against the SARSCoV- 2. Our study, although preliminary, suggests the autovaccine as a possible prophylactic treatment that may contribute to the fight against COVID-19. Larger cohorts and randomized controlled trials are urgently needed to confirm these results.

Funding

No funding was received for this work.

Conf Lists of Interest

Jaime Leache Pueyo has no conflict of interest. Laura Pérez Delgado has no conflict of interest. José Victor Tisner Nieto has no conflict of interest. Mª Carmen Orte Aldea has no conflict of interest. Raquel Artal Sánchez has no conflict of interest.

María Matas Ros is an employee of Probelte Pharma.

Inmaculada Buendía Jiménez is an employee of Probelte Pharma.

References

Research Article

Proof of Concept Study to Investigate the Association Between Autovaccines and COVID-19 Incidence in Patients with Recurrent Respiratory Diseases

Jaime Leache Pueyo1, Laura Pérez Delgado1, José Victor Tisner Nieto2, Mª Carmen Orte Aldea3, Raquel Artal Sánchez2, María Matas Ros4 and Inmaculada Buendía Jiménez4*

Author Affiliations

1Hospital Universitario Miguel Servet, ENT Service, Zaragoza, Spain

2ENT Clinic, Zaragoza, Spain

3ENT Service, Huesca, Spain

4Probelte Pharma S.L.U, Murcia, Spain

Received: June 01, 2021 | Published: June 11, 2021

Corresponding author: Inmaculada Buendía Jiménez, Probelte Pharma S.L.U, Murcia, Spain

DOI: 10.26717/BJSTR.2021.36.005853

Abstract

Introduction: Exposure to bacterial components can activate innate immunity and “train” it.

This phenomenon is crucial in the fight against infectious diseases, including COVID-19. The objective of this study is to assess whether a bacterial autovaccine could protect against SARS-CoV-2 thanks to trained innate immunity.

Methods: A retrospective controlled study that was carried out in four ENT services in Spain. Patients aged between 18 and 80 years of age with recurrent upper respiratory tract infections who received the bacterial autovaccine during a period between January 2019 and April 2020 were selected. The control group was made up of a selection of patients who presented a pathology in the ENT area and who did not receive the bacterial autovaccine during the same period. The study was approved by the regional Ethics Committee of Aragon. The main parameter was cumulative incidence, i.e., the proportion of people who contracted COVID-19 and had been diagnosed by PCR or serology in the period between March and August 2020 in each group.

Results: 129 patients were included in the autovaccine group and 149 patients in the control group. Both groups had a similar demographic and clinical distribution. The group treated with the autovaccine had a significantly lower incidence of COVID-19 than the control group (2.3% vs 8.7%, p <0.05).

Conclusion: These results suggest that the bacterial autovaccine could protect against COVID-19 as the cumulative incidence in the autovaccine group is almost four times lower than in the control group. Controlled clinical trials are necessary to confirm these data.

Keywords: Autovaccine; Bacterial Lysate; COVID-19; Trained Innate Immunity